Chen et al. depicted that the increased efficacy of the drug Lenvatinib, which is an FDA- approved drug for the HCC treatment was found with the knockdown of MKLN1 due to the increased apoptosis in the HCC [87]. Here, MKLN1 is linked to hepatocellular carcinoma.